| Literature DB >> 31978221 |
Alexander Röth1, Jun-Ichi Nishimura2, Zsolt Nagy3, Julia Gaàl-Weisinger3, Jens Panse4, Sung-Soo Yoon5, Miklos Egyed6, Satoshi Ichikawa7, Yoshikazu Ito8, Jin Seok Kim9, Haruhiko Ninomiya10, Hubert Schrezenmeier11,12, Simona Sica13, Kensuke Usuki14, Flore Sicre de Fontbrune15, Juliette Soret16, Alexandre Sostelly17, James Higginson18, Andreas Dieckmann17, Brittany Gentile19, Judith Anzures-Cabrera18, Kenji Shinomiya20, Gregor Jordan21, Marta Biedzka-Sarek17, Barbara Klughammer17, Angelika Jahreis19, Christoph Bucher17, Régis Peffault de Latour22,23.
Abstract
Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms. Constant and complete suppression of the terminal complement pathway and the high serum concentration of C5 pose challenges to drug development that result in IV-only treatment options. Crovalimab, a sequential monoclonal antibody recycling technology antibody was engineered for extended self-administered subcutaneous dosing of small volumes in diseases amenable for C5 inhibition. A 3-part open-label adaptive phase 1/2 trial was conducted to assess safety, pharmacokinetics, pharmacodynamics, and exploratory efficacy in healthy volunteers (part 1), as well as in complement blockade-naive (part 2) and C5 inhibitor-treated (part 3) PNH patients. Twenty-nine patients were included in part 2 (n = 10) and part 3 (n = 19). Crovalimab concentrations exceeded the prespecified 100-µg/mL level and resulted in complete and sustained terminal complement pathway inhibition in treatment-naive and C5 inhibitor-pretreated PNH patients. Hemolytic activity and free C5 levels were suppressed below clinically relevant thresholds (liposome assay <10 U/mL and <50 ng/mL, respectively). Safety was consistent with the known profile of C5 inhibition. As expected, formation of drug-target-drug complexes was observed in all 19 patients switching to crovalimab, manifesting as transient mild or moderate vasculitic skin reactions in 2 of 19 participants. Both events resolved under continued treatment with crovalimab. Subcutaneous crovalimab (680 mg; 4 mL), administered once every 4 weeks, provides complete and sustained terminal complement pathway inhibition in patients with PNH, warranting further clinical development (ClinicalTrials.gov identifier, NCT03157635).Entities:
Mesh:
Substances:
Year: 2020 PMID: 31978221 PMCID: PMC7082616 DOI: 10.1182/blood.2019003399
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113